The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
CAR-T Meeting 2020 | ICU admission of patients treated with ARI-0001 cells
Valentín Ortiz-Maldonado, MD, Hospital Clinic, Barcelona, Spain, discusses the safety of ARI-0001 cells (varnimcabtagene autoleucel), an academic CD19 CAR T-cell, in patients with CD19+ leukemia or lymphoma refractory to therapy. The clinical trial (NCT03144583) protocol had to be changed due to toxicities, such as cytokine release syndrome (CRS). Dr Ortiz-Maldonado explains how splitting the doses of ARI-cells reduced patients’ admission in the ICU. This interview took place at the 2nd European CAR T-Cell Meeting in Sitges, Spain.
